Drugs / Recombinant Humanized Anti-CD52 Monoclonal Antibody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05557903 | Dec 2021 → Dec 2022 | T-cell non-Hodgkin lymphoma | Lanzhou Institute of Biological Products Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Humanized Anti-CD52 Monoclonal Antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05557903 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT05557903 ↗ |
| Target | CD52 | “anti-CD52 monoclonal antibody” NCT05557903 ↗ |